RecruitingPHASE1, PHASE2NCT04771130

A Study of BGB-11417 in Participants With Myeloid Malignancies

Studying Myeloproliferative neoplasm

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: BeiGene
Intervention: BGB-11417(drug)
Enrollment: 260 target
Eligibility: 18 years · All sexes
Timeline: 2021 – 2028

Study locations (30)

City of Hope National Medical Center, Duarte, California, United States
Tampa General Hospital, Tampa, Florida, United States
Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania, United States
Md Anderson Cancer Center, Houston, Texas, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Concord Repatriation General Hospital, Concord, New South Wales, Australia
St George Hospital, Kogarah, New South Wales, Australia
Orange Health Hospital, Orange, New South Wales, Australia
Gold Coast University Hospital, Southport, Queensland, Australia
Monash Health, Clayton, Victoria, Australia
St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
The Alfred Hospital, Melbourne, Victoria, Australia
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Linear Clinical Research, Nedlands, Western Australia, Australia
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04771130 on ClinicalTrials.gov

Other trials for Myeloproliferative neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Myeloproliferative neoplasm →

← Back to all trials